Quality of Life and Subgroup Analysis in a Phase 3 Randomized Study of Ensartinib vs Crizotinib in ALK-Positive NSCLC Patients: eXalt3.
No Thumbnail Available
Date
2021
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Science Inc
Access Rights
info:eu-repo/semantics/closedAccess
Abstract
[Abstract Not Available]
Description
Keywords
ALK, NSCLC, Ensartinib
Journal or Series
Journal Of Thoracic Oncology
WoS Q Value
Q1
Scopus Q Value
Volume
16
Issue
3
